How RenovoRx’s TAMP platform data could reshape intra-arterial drug delivery in pancreatic cancer
RenovoRx’s ASCO 2026 data highlights how targeted gemcitabine delivery could reshape pancreatic cancer treatment strategy. Read more.
Why Sapu Nano’s Deciparticle platform could become a broader oncology drug-delivery play
Discover how Sapu Nano’s Deciparticle platform could reshape oncology drug delivery and expand intravenous everolimus development.
Can OncoNano Medicine’s ON-BOARD platform solve antigen limits in solid tumor drug delivery?
OncoNano Medicine’s AACR 2026 data spotlight ON-BOARD and ONM-421. Read why pH-targeted tumor delivery could reshape oncology development.
Avacta’s pre|CISION exatecan conjugate reaches Phase 1 as competition in targeted topo I inhibitors intensifies
Avacta opens Phase 1 trial of FAP-Exd (AVA6103) in four advanced solid tumors. Analysis of what the sustained-release exatecan conjugate must prove in 2026.
Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start
Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves […]
Starton Therapeutics advances STAR-LLD as delivery innovation in multiple myeloma
Starton Therapeutics advances STAR-LLD in Phase 2a. Explore how continuous lenalidomide delivery could reshape multiple myeloma care.
Can subcutaneous infusion disrupt oncology workflows? Inside KORU Medical’s 510(k) strategy for FreedomEDGE
KORU Medical’s 510(k) filing for FreedomEDGE with PHESGO could reshape subcutaneous cancer therapy. Find out what this means for oncology care delivery.